Document is current
Any future updates will be listed below
-
Authors
Ciracì, Paolo https://orcid.org/0000-0002-3791-6288
Studiale, Vittorio
Taravella, Ada https://orcid.org/0009-0000-2153-3867
Antoniotti, Carlotta
Cremolini, Chiara https://orcid.org/0000-0002-0520-4841
- License Information
-
More Information
Article History
Accepted: 25 October 2024
First Online: 18 November 2024
Competing interests
: C.C. has acted as an adviser and/or consultant of AstraZeneca, Lilly, Merck, MSD, Nordic Pharma, Roche, Pierre Fabre, Takeda and Tempus; declares speaker’s fees from Amgen, Bayer, MSD, Merck Serono, Pierre Fabre, Servier and Takeda; and has received research grants from Amgen, Merck, Pierre Fabre, Roche, Seagen (Pfizer), Servier, Tempus. C.A. has acted as a consultant and/or adviser of Takeda and has received speaker’s fees from Merck. The other authors declare no competing interests.
